Attovia Therapeutics, Inc. (ATTO) stock
ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026
$14.86+0.13 (+0.92%)
Close on Nov 17, 2026Market cap $678.38MP/E –Yield –
Attovia Therapeutics cash
Cash and short-term investments held at the end of each period.
Attovia Therapeutics's cash was $395.94M at Sep 30, 2026. For fiscal 2025 it was $152.27M, up 387.4% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $152.27M | +387.4% |
| FY2024 | Dec 31, 2024 | $31.24M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $395.94M | +828.5% |
| Q2 FY2026 | Jun 30, 2026 | $115.13M | +268.6% |
| Q4 FY2025 | Dec 31, 2025 | $152.27M | – |
| Q3 FY2025 | Sep 30, 2025 | $49.77M | – |
| Q2 FY2025 | Jun 30, 2025 | $42.65M | – |
| Q4 FY2024 | Dec 31, 2024 | $31.24M | – |
See a number that looks wrong?